Cellular Therapy
From the Journals
CAR-T outcomes similar among diverse cancer patients
Black, Hispanic, White, and Asian cancer patients showed comparable responses to CAR-T therapy, a study indicates.
Latest News
FDA approves new CAR T-cell treatment for multiple myeloma
Study results show that this treatment for refractory/relapsed multiple myeloma can provide deep, durable responses and long treatment-free...
Latest News
EMA gives green light to new CAR T-cell therapy
The committee also recommended approval of a biosimilar product for pegfilgrastim.
From the Journals
CLL patients ‘cured’: 10 years post infusion, CAR T cells persist
A decade after CAR T’cell treatment, chronic leukemia patients reported “cured,” with cells still detectable.
Feature
DKMS: Small nonprofit to world’s largest stem cell donor registry
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
Conference Coverage
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...
Conference Coverage
CAR-T in children branching out to solid tumors
Conference Coverage
Using engineered T cells reduced acute, chronic GVHD
Conference Coverage
Novel ddPCR assay precisely measures CAR T-cells after infusion
Conference Coverage
CAR T-cell products shine in real-world setting, reveal new insights
Real-world CAR-T experience provides new insights for predicting outcomes in patients with DLBCL.
Video
Experts break down latest CAR T-cell advances in lymphoma
ORLANDO – An expert panel of physicians discusses the latest research on CAR T-cell therapy in lymphoma, presented at the 2019 annual meeting of...